A Tissue Systems Pathology Assay for High-Risk Barrett's Esophagus

Area of Science:

• Gastroenterology and Oncology
• Biomarker Discovery
• Pathology

Background:

• Barrett's esophagus (BE) carries a risk of progression to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC).
• Accurate prediction of BE progression is crucial for effective patient management.
• Current methods for risk stratification have limitations.

Purpose of the Study:

• To develop and validate a novel tissue systems pathology approach for predicting progression in Barrett's esophagus.
• To assess the utility of quantifying epithelial and stromal variables in baseline biopsies.

Main Methods:

• A nested case-control study involving 79 progressing and 287 non-progressing Barrett's esophagus patients.
• Development and validation of a 15-feature classifier using immunofluorescence and quantitative morphometric analyses.
• Comparison of the classifier's predictive performance against traditional clinicopathologic variables.

Main Results:

• A 3-tier classifier accurately stratified patients into low-, intermediate-, and high-risk groups for progression.
• The classifier demonstrated significant prognostic value (HR, 9.42; P < 0.0001).
• The tissue systems pathology test outperformed predictions based on conventional pathology, patient demographics, and p53 overexpression.

Conclusions:

• A tissue systems pathology test was developed that significantly improves the prediction of Barrett's esophagus progression risk.
• This objective test has the potential to enhance histologic analysis for risk stratification of Barrett's esophagus patients.